Wang N. .2021 ."An optimized method for the detection and spatial distribution of aminoglycoside and vancomycin antibiotics in tissue sections by mass spectrometry imaging". Journal of Mass Spectrometry, : .
Ahmed M.E. .2025 ."Bacteriocin isolated from Ralstonia mannitolilytica and bacteriocin-capped silver nanoparticles: comparative effects on biofilm formation and LuxS gene's expressions by Proteus mirabilis as an approach to counter MDR catheter infection". Microbial Pathogenesis, 107558 : .
Wiesenfeld S.L.,Weber W.W. . ."Tissue distribution of vancomycin in normal and infected mice". Journal of Antibiotics, 30(1977) : 312-318.
Tröger U. . ."Tissue distribution and plasma kinetics of vancomycin in rats after single and repeated dosing". Journal of Antimicrobial Chemotherapy, 33(1994) : 789-799.
Rybak M.J. . ."Therapeutic monitoring of vancomycin in adult patients". American Journal of Health-System Pharmacy, 66(2009) : 82-98.
Joshi M.D. . ."Pharmacokinetics and biodistribution of vancomycin after systemic administration in animal models". Pharmaceutics, 15(2023) : 1582.
Cai Q. .2015 ."Quantification of vancomycin in rat plasma and tissues by LC-MS/MS and its application to pharmacokinetic studies". Journal of Pharmaceutical and Biomedical Analysis, 115 : 515-520.
Chakraborty S.P. . ."Amelioratory effect of nanoconjugated vancomycin on MRSA-infected mice: biodistribution and toxicity analysis". Journal of Nanobiotechnology, 9(2011) : 27.
Levine D.P. . ."Vancomycin: a history". Clinical Infectious Diseases, 1(2006) : S5-S12.
Howden B.P. . ."Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications". Clinical Microbiology Reviews, 23(2010) : 99-139.
Kahne D. . ."Glycopeptide and lipoglycopeptide antibiotics". Chemical Reviews, 105(2005) : 425-448.
Matzke G.R.,Zhanel G.G.,Guay D.R.P. . ."Clinical pharmacokinetics of vancomycin". Clinical Pharmacokinetics, 11(1986) : 257-282.
Rybak M.J. . ."Therapeutic monitoring of vancomycin in adult patients". American Journal of Health-System Pharmacy, 66(2009) : 82-98.
Joshi M.D. . ."Pharmacokinetics and biodistribution of vancomycin after systemic administration in animal models". Pharmaceutics, 15(2023) : 1582.
Tröger U. . ."Tissue distribution and plasma kinetics of vancomycin in rats after single and repeated dosing". Journal of Antimicrobial Chemotherapy, 33(1994) : 789-799.
Elkomy A. . ."Hepatic and renal protective effects of antioxidants against vancomycin-induced toxicity in rats". Toxicology Reports, 5(2018) : 844-852.
Ozkan F. .2021 ."Histopathological and biochemical effects of vancomycin on liver and kidney tissues in rats". Human & Experimental Toxicology, 40(10) : 1757-1768.
Wiesenfeld S.L.,Weber W.W. . ."Tissue distribution of vancomycin in normal and infected mice". Journal of Antibiotics, 30(1977) : 312-318.
Al-Awadi A.Q. .2025 ."Antibacterial and therapeutic effects of vancomycin-resistant Staphylococcus aureus bacteriocin (VRSAcin) in the treatment of VRSA skin infection in mice". Microbial Pathogenesis, 107729 : .
Bosso J.A. .2011 ."Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial". Antimicrobial Agents and Chemotherapy, 55(12) : 5475-5479.
Joshi M.D. . ."Pharmacokinetics and biodistribution of vancomycin after systemic administration in animal models". Pharmaceutics, 15(2023) : 1582.